ADDED
As of April 15, 2026, the registrant had 33,717,143 ordinary shares outstanding (inclusive of shares included in outstanding units).
On June 17, 2024, we issued to Drugs Made In America Acquisition LLC, our sponsor, an aggregate of 22,361,111 ordinary shares (the founder shares ) for an aggregate purchase price of $35,000, or approximately $0.0016 per share.
Simultaneously with the closing of the IPO, we consummated the private placement with our sponsor of 400,000 units (the Private Placement Units ) at a price of $10.00 per unit, for $4,000,000.
There is no guarantee that our shareholders at the extraordinary general meeting will approve this proposal.
Recent Developments The ordinary shares and rights comprising the units began separate trading on February 25, 2025.
On October 8, 2025, Glenn Worman, the former Chief Financial Officer and principal financial and accounting officer of the Company delivered to the Company a notice of resignation from his position as Chief Financial Officer and principal financial and accounting officer of the Company.
Worman indicated that his resignation was not the result of any disagreement with the Company regarding its operations, policies, practices or otherwise.
On November 17, 2025, the Company appointed Saleem Elmasri as Chief Financial Officer and principal financial and accounting officer of the Company and entered into a Master Services Agreement (the Consulting Agreement ) with Titan Advisory Services LLC for the provision of such principal financial and accounting officer services by Mr.
Elmasri s appointment to principal financial and accounting officer of the Company was effective November 17, 2025.
Under the terms of the Consulting Agreement, the Company will pay Titan Advisory Services LLC $42,000 per year, or $3,500 per month, for services rendered by Mr.
REMOVED
As of March 28, 2025, the registrant had 33,517,143 ordinary shares outstanding (inclusive of shares included in outstanding units).
On June 17, 2024, we issued to the sponsor an aggregate of 22,361,111 ordinary shares (the founder shares ) for an aggregate purchase price of $35,000, or approximately $0.0016 per share.
Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a pharmaceutical business in the United States.
Business Strategy Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the pharmaceutical industry.
We believe our management team s knowledge, decades of experience and relationships across this industry can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within the pharmaceutical industry.
Although the pharmaceutical industry is highly regulated, and there are many legal and regulatory considerations that companies must consider, such as licensing requirements, export controls, and liability issues, we believe our sponsor s expertise and track record in the pharmaceutical space will help mitigate these factors by proactively advising potential target companies on navigating these issues.
medical supply chain by investing in companies that will reduce America s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
To achieve these goals, we will aim to complete our initial business combination with one or more target companies that can deliver a solution to (1) the lack of supply chain visibility into where and by whom critical drug products are manufactured and (2) the inability to accurately predict and proactively relieve ongoing and future drug shortages.
2 We believe that we have an important role in the future of the pharmaceutical business.
With a successful series of target acquisitions the result will be a fully integrated competitive cost business with vast expertise.